Company Info

Partnerships and Collaborations

Celgene Corporation

On August 22, 2016, MetaStat executed a pilot materials transfer agreement (the “MTA”) with Celgene Corporation (“Celgene”) to conduct a mutually agreed upon pilot research project. On September 29, 2016, we entered into an amendment (the “Amendment”) to the MTA (the “Amendment,” and together with the MTA, the “Research Agreement”), which provided for milestone payments to MetaStat of up to approximately $973,000. Under the terms of the Research Agreement, Celgene provided certain proprietary materials to the Company and the Company evaluated Celgene’s proprietary materials in the Company’s metastatic cell line (in vitro) and animal (in vivo) nonclinical models. The Pilot Project was successfully completed in January 2018.

Albert Einstein College of Medicine and Montefiore Medical Center

Effective January 9, 2015, MetaStat executed a collaboration agreement (the “Collaboration Agreement”) with Albert Einstein College of Medicine and Montefiore Medical Center to collaborate on research projects, including conducting studies that establish the clinical validity and clinical utility of MetaStat’s prognostic diagnostic tests, including the MetaSite Breast™ test, the MenaCalc™ test, and a combined MetaSite Breast™ and MenaCalc™ test. The term of the Collaboration Agreement is five years, which may be terminated by either party with thirty days written notice.

National Institutes of Health, National Cancer Institute

Effective September 21, 2016, MetaStat executed an agreement with the National Institutes of Health, National Cancer Institute (the “NCI"), whereby the NCI will contract with MetaStat to perform the MetaSite Breast™ and MenaCalc™ analysis of breast cancer tumor tissue as part of a clinical study. In addition, MetaStat will collaborate with the Department of Cancer Epidemiology and Genetics (DCEG) at the NCI on interpretation of the study analysis and dissemination of results.